A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer.

Saved in:
Bibliographic Details
Title: A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer.
Authors: Rustin, G.1, Vergote, I.2, Micha, J.P.3, Duska, L.R.4, Reed, N.5, Bendell, J.6, Spitz, D.7, Dark, G.8, Hoch, U.9, Tagliaferri, M.9, Hannah, A.L.9, Garcia, A.A.10,11 agarc6@lsuhsc.edu
Source: Gynecologic Oncology. Nov2017, Vol. 147 Issue 2, p276-282. 7p.
Database: Academic Search Ultimate
Description
ISSN:00908258
DOI:10.1016/j.ygyno.2017.08.026